Comparative trial of labetalol and acebutolol, alone or associated with dihydralazine, in treatment of essential hypertension.

1 Labetalol, an alpha- and beta- adrenoceptor blocking drug, was compared with acebutolol, alone or associated with dihydralazine in forty patients with moderate essential hypertension. 2 Labetalol (400--800 mg daily) seemed to have a slightly higher potency than acebutolol alone (400--800 mg daily). 3 Labetalol (1200--1600 mg daily) had the same potency as the combination of acebutolol (400--800 mg daily) and dihydralazine (50--100 mg daily). 4 Contrarily to acebutolol, the drop in blood pressure with labetalol was not correlated with initial plasma renin activity. 5 Labetalol side effects were minor and did not lead to drug withdrawal.

RCT Entities:   Population Interventions Outcomes